Cardiovascular Effects of High-Frequency Magnetic Seizure Therapy Compared With Electroconvulsive Therapy.
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
28
2
2022
medline:
31
8
2022
entrez:
27
2
2022
Statut:
ppublish
Résumé
Magnetic seizure therapy (MST) is a novel convulsive therapy that has been shown to have antidepressant efficacy comparable to electroconvulsive therapy (ECT) with fewer cognitive side effects. However, the cardiovascular (CVS) effects of high frequency MST in comparison to ECT have not been investigated. Forty-five patients with depression received 6 treatment sessions of 100 Hz MST versus 6 bifrontal ECT treatments in a nonrandomized comparative clinical design. Data on CVS function including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and rate pressure product (RPP) were collected at baseline (T0), after the induction of anesthesia but before the electrical stimulation (T1), during convulsion (T2), 2 minutes after cessation of motor seizure (T3), 5 minutes after cessation of motor seizure (T4), and 10 minutes after cessation of motor seizure (T5). Comparisons were made with baseline data and between MST and ECT groups. There were statistically significant elevations in the maximum HR, SBP, DBP, and RPP in patients receiving ECT compared with MST both in the initial and sixth treatments (all P < 0.05). Particularly, at T2, the ECT group had significantly higher HR, SBP, DBP, and RPP than those in MST group both in initial and sixth treatment (all P < 0.001). At the sixth treatment, the ECT group had significantly higher SBP, DBP, and RPP during the treatment than in the MST group (all P < 0.001). The anesthetic choices for this study may limit the generalizability of our findings. The sample size was relatively small. Compared with ECT, high-frequency MST has fewer CVS side effects and may be a safer option for depression patients with CVS disorders.
Sections du résumé
BACKGROUND
Magnetic seizure therapy (MST) is a novel convulsive therapy that has been shown to have antidepressant efficacy comparable to electroconvulsive therapy (ECT) with fewer cognitive side effects. However, the cardiovascular (CVS) effects of high frequency MST in comparison to ECT have not been investigated.
MATERIALS AND METHODS
Forty-five patients with depression received 6 treatment sessions of 100 Hz MST versus 6 bifrontal ECT treatments in a nonrandomized comparative clinical design. Data on CVS function including heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and rate pressure product (RPP) were collected at baseline (T0), after the induction of anesthesia but before the electrical stimulation (T1), during convulsion (T2), 2 minutes after cessation of motor seizure (T3), 5 minutes after cessation of motor seizure (T4), and 10 minutes after cessation of motor seizure (T5). Comparisons were made with baseline data and between MST and ECT groups.
RESULTS
There were statistically significant elevations in the maximum HR, SBP, DBP, and RPP in patients receiving ECT compared with MST both in the initial and sixth treatments (all P < 0.05). Particularly, at T2, the ECT group had significantly higher HR, SBP, DBP, and RPP than those in MST group both in initial and sixth treatment (all P < 0.001). At the sixth treatment, the ECT group had significantly higher SBP, DBP, and RPP during the treatment than in the MST group (all P < 0.001).
LIMITATIONS
The anesthetic choices for this study may limit the generalizability of our findings. The sample size was relatively small.
CONCLUSIONS
Compared with ECT, high-frequency MST has fewer CVS side effects and may be a safer option for depression patients with CVS disorders.
Identifiants
pubmed: 35220358
doi: 10.1097/YCT.0000000000000833
pii: 00124509-202209000-00011
pmc: PMC9422761
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-191Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest or financial disclosures to report.
Références
UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet . 2003;361:799–808.
Gravenstein JS, Anton AH, Wiener SM, et al. Catecholamine and cardiovascular response to electro-convulsion therapy in man. Br J Anaesth . 1965;37:833–839.
Mann JJ, Manevitz AZ, Chen JS, et al. Acute effects of single and repeated electroconvulsive therapy on plasma catecholamines and blood pressure in major depressive disorder. Psychiatry Res . 1990;34:127–137.
Stewart PT, Loo CK, MacPherson R, et al. The effect of electrode placement and pulsewidth on asystole and bradycardia during the electroconvulsive therapy stimulus. Int J Neuropsychopharmacol . 2011;14:585–594.
Nagler J. Heart rate changes during electroconvulsive therapy. Ann General Psychiatry . 2013;12:19.
Landau AM, Chakravarty MM, Clark CM, et al. Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology . 2011;36:511–518.
Hageman I, Nielsen M, Wortwein G, et al. Electroconvulsive stimulations prevent stress-induced morphological changes in the hippocampus. Stress . 2008;11:282–289.
Phutane VH, Thirthalli J, Muralidharan K, et al. Double-blind randomized controlled study showing symptomatic and cognitive superiority of bifrontal over bitemporal electrode placement during electroconvulsive therapy for schizophrenia. Brain Stimul . 2013;6:210–217.
Abhishekh HA, Anusha M, Thirthalli J, et al. Cardiovascular responses are similar in bifrontal and bitemporal ECT. J ECT . 2012;28:194.
Jurek L, Dorey JM, Nourredine M, et al. Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy. J Affect Disord . 2021;279:308–315.
Kayser S, Bewernick BH, Soehle M, et al. Degree of postictal suppression depends on seizure induction time in magnetic seizure therapy and electroconvulsive therapy. J ECT . 2017;33:167–175.
Kayser S, Bewernick BH, Grubert C, et al. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. J Psychiatr Res . 2011;45:569–576.
Farzan F, Atluri S, Mei Y, et al. Brain temporal complexity in explaining the therapeutic and cognitive effects of seizure therapy. Brain . 2017;140:1011–1025.
Lisanby SH, Luber B, Schlaepfer TE, et al. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology . 2003;28:1852–1865.
Kayser S, Bewernick BH, Wagner S, et al. Effects of magnetic seizure therapy on anterograde and retrograde amnesia in treatment-resistant depression. Depress Anxiety . 2020;37:125–133.
Fitzgerald PB, Hoy KE, Elliot D, et al. A pilot study of the comparative efficacy of 100 Hz magnetic seizure therapy and electroconvulsive therapy in persistent depression. Depress Anxiety . 2018;35:393–401.
Wang J, Vila-Rodriguez F, Ge R, et al. Accelerated magnetic seizure therapy (aMST) for treatment of major depressive disorder: a pilot study. J Affect Disord . 2020;264:215–220.
Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. Lancet . 1985;1:1106–1107.
George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry . 1999;56:300–311.
Kirov G, Ebmeier KP, Scott AI, et al. Quick recovery of orientation after magnetic seizure therapy for major depressive disorder. Br J Psychiatry . 2008;193:152–155.
Zhang J, Ren Y, Jiang W, et al. Shorter recovery times and better cognitive function-a comparative pilot study of magnetic seizure therapy and electroconvulsive therapy in patients with depressive episodes. Brain Behav . 2020;10:e01900.
Devinsky O. Effects of seizures on autonomic and cardiovascular function. Epilepsy Curr . 2004;4:43–46.
Opherk C, Coromilas J, Hirsch LJ. Heart rate and EKG changes in 102 seizures: analysis of influencing factors. Epilepsy Res . 2002;52:117–127.
Rowny SB, Cycowicz YM, McClintock SM, et al. Differential heart rate response to magnetic seizure therapy (MST) relative to electroconvulsive therapy: a nonhuman primate model. NeuroImage . 2009;47:1086–1091.
White PF, Amos Q, Zhang Y, et al. Anesthetic considerations for magnetic seizure therapy: a novel therapy for severe depression. Anesth Analg . 2006;103:76–80, table of contents.
Fitzgerald PB, Hoy KE, Herring SE, et al. Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder. Depress Anxiety . 2013;30:129–136.
First MB, Spitzer RL, Gibbon ML, Williams JBW. Structured clinical interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. 2002.
A Rating Scale for Depression. J Neurol Neurosurg Psych . 1960;23:56–62.
Klem GH, Lüders HO, Jasper HH, et al. The ten-twenty electrode system of the international federation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl . 1999;52:3–6.
Cretaz E, Brunoni AR, Lafer B. Magnetic seizure therapy for unipolar and bipolar depression: a systematic review. Neural Plast . 2015;2015:521398.
Milev RV, Giacobbe P, Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 4. Neurostimulation Treatments. Can J Psychiatr . 2016;61:561–575.
de Sousa RT, Zanetti MV, Brunoni AR, et al. Challenging treatment-resistant major depressive disorder: a roadmap for improved therapeutics. Curr Neuropharmacol . 2015;13:616–635.
Petrides G, Fink M. The "half-age" stimulation strategy for ECT dosing. Convuls Ther . 1996;12:138–146.
Holm S. A simple sequentially rejective multiple test procedure. Scand Stat Theory Appl . 1979;6:65–70.
Lee WH, Lisanby SH, Laine AF, et al. Comparison of electric field strength and spatial distribution of electroconvulsive therapy and magnetic seizure therapy in a realistic human head model. Eur Psychiatry . 2016;36:55–64.
Welch CA, Drop LJ. Cardiovascular effects of ECT. Convuls Ther . 1989;5:35–43.
Deng ZD, Lisanby SH, Peterchev AV. Electric field strength and focality in electroconvulsive therapy and magnetic seizure therapy: a finite element simulation study. J Neural Eng . 2011;8:016007.
Aydogan MS, Yücel A, Begec Z, et al. The hemodynamic effects of dexmedetomidine and esmolol in electroconvulsive therapy: a retrospective comparison. J ECT . 2013;29:308–311.
Castelli I, Steiner LA, Kaufmann MA, et al. Comparative effects of esmolol and labetalol to attenuate hyperdynamic states after electroconvulsive therapy. Anesth Analg . 1995;80:557–561.
Parikh DA, Garg SN, Dalvi NP, et al. Outcome of four pretreatment regimes on hemodynamics during electroconvulsive therapy: a double-blind randomized controlled crossover trial. Ann Card Anaesth . 2017;20:93–99.
Tsen P, El Mansari M, Blier P. Effects of repeated electroconvulsive shocks on catecholamine systems: electrophysiological studies in the rat brain. Synapse . 2013;67:716–727.
Ito M, Hatta K, Usui C, et al. Urine catecholamine levels are not influenced by electroconvulsive therapy in depression or schizophrenia over the long term. Psychiatry Clin Neurosci . 2012;66:602–610.
Rasmussen KG. Propofol for ECT anesthesia a review of the literature. J ECT . 2014;30:210–215.